Literature DB >> 10507761

Paradoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7.

L K Leung1, T T Wang.   

Abstract

Tumorigenesis is related to the dysregulation of cell growth or cell death pathways. Hence, elucidation of the mechanisms involved in the modulation of pro- or anti-apoptotic proteins is important in furthering understanding of breast cancer aetiology and may aid in designing prevention and treatment strategies. In the present study, we examined the role of 17beta-oestradiol on the regulation of apoptosis in the breast cancer cell line MCF-7. Using multi-probe RNAase protection assays, we found changes in the mRNA levels of several Bcl-2 family proteins upon treatment of MCF-7 cells with 17beta-oestradiol. Unexpectedly, we found a paradoxical effects of 17beta-oestradiol on two anti-apoptotic proteins Bcl-2 and Bcl-x. Treatment with 17beta-oestradiol resulted in up-regulation of Bcl-2 mRNA and protein, but down-regulated Bcl-x(L) mRNA and protein. The effect of 17beta-oestradiol on Bcl-x(L) occurred at concentration-dependent fashion. The effect was specific to 17beta-oestradiol since other steroid hormones exert no effect on Bcl-x(L). Tamoxifen, an anti-oestrogen, blocked the down-regulation of Bcl-x(L) by 17beta-oestradiol demonstrating this effect is oestrogen receptor-dependent. We speculate that different members of the Bcl-2 family proteins may be regulated through different pathway and these pathways may be modulated by 17beta-oestradiol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507761      PMCID: PMC2362930          DOI: 10.1038/sj.bjc.6690706

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

1.  Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells.

Authors:  C Teixeira; J C Reed; M A Pratt
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

Review 2.  Death receptors: signaling and modulation.

Authors:  A Ashkenazi; V M Dixit
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

3.  Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K.

Authors:  S N Farrow; J H White; I Martinou; T Raven; K T Pun; C J Grinham; J C Martinou; R Brown
Journal:  Nature       Date:  1995-04-20       Impact factor: 49.962

Review 4.  The role of estrogen in mammary carcinogenesis.

Authors:  J Fishman; M P Osborne; N T Telang
Journal:  Ann N Y Acad Sci       Date:  1995-09-30       Impact factor: 5.691

5.  Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis.

Authors:  R C Bargou; P T Daniel; M Y Mapara; K Bommert; C Wagener; B Kallinich; H D Royer; B Dörken
Journal:  Int J Cancer       Date:  1995-03-16       Impact factor: 7.396

6.  Involvement of the bcl-2 gene in human follicular lymphoma.

Authors:  Y Tsujimoto; J Cossman; E Jaffe; C M Croce
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

7.  Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.

Authors:  N Kyprianou; H F English; N E Davidson; J T Isaacs
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

8.  Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7.

Authors:  T T Wang; J M Phang
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

9.  A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions.

Authors:  T Chittenden; C Flemington; A B Houghton; R G Ebb; G J Gallo; B Elangovan; G Chinnadurai; R J Lutz
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

Review 10.  Bcl-2 and the regulation of programmed cell death.

Authors:  J C Reed
Journal:  J Cell Biol       Date:  1994-01       Impact factor: 10.539

View more
  16 in total

1.  Bcl-2 antigen expression in luminal A and triple-negative breast cancer.

Authors:  Carla Solange Escórcio-Dourado; Luana Mota Martins; Camila Maria Simplício-Revoredo; Fabiane Araújo Sampaio; Cléciton Braga Tavares; João Paulo da Silva-Sampaio; Umbelina Soares Borges; Francisco Adelton Alves-Ribeiro; Pedro Vitor Lopes-Costa; José Charles Lima-Dourado; Benedito Borges da Silva
Journal:  Med Oncol       Date:  2017-08-11       Impact factor: 3.064

Review 2.  Significance of immunohistochemistry in breast cancer.

Authors:  Dana Carmen Zaha
Journal:  World J Clin Oncol       Date:  2014-08-10

3.  ERα and ERβ expression in correlation with Ki-67, Bcl-2 and Bak in primary tumors and lymph node metastases of breast cancer: The effect of pre-operative chemotherapy.

Authors:  Luiza Kanczuga-Koda; Mariusz Koda; Jakub Tomaszewski; Katarzyna Jarzabek; Joanna Lotowska; Marek Baltaziak; Urszula Sulkowska; Maria Sobaniec-Lotowska; Stanisław Sulkowski
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

4.  Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt.

Authors:  Romaine Ingrid Fernando; Jay Wimalasena
Journal:  Mol Biol Cell       Date:  2004-04-30       Impact factor: 4.138

5.  The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis.

Authors:  Jingyung Hur; Jessica Chesnes; Kathryn R Coser; Roseanna S Lee; Peter Geck; Kurt J Isselbacher; Toshi Shioda
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

Review 6.  Molecular markers for predicting response to tamoxifen in breast cancer patients.

Authors:  D R Ciocca; R Elledge
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.925

7.  BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.

Authors:  S-J Dawson; N Makretsov; F M Blows; K E Driver; E Provenzano; J Le Quesne; L Baglietto; G Severi; G G Giles; C A McLean; G Callagy; A R Green; I Ellis; K Gelmon; G Turashvili; S Leung; S Aparicio; D Huntsman; C Caldas; P Pharoah
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

8.  A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Authors:  Julie A Vendrell; Katherine E Robertson; Patrice Ravel; Susan E Bray; Agathe Bajard; Colin A Purdie; Catherine Nguyen; Sirwan M Hadad; Ivan Bieche; Sylvie Chabaud; Thomas Bachelot; Alastair M Thompson; Pascale A Cohen
Journal:  Breast Cancer Res       Date:  2008-10-17       Impact factor: 6.466

9.  Enhanced micronucleus formation and modulation of BCL-2:BAX in MCF-7 cells after exposure to binary mixtures.

Authors:  Rebecca Hewitt; Albert Forero; Paz J Luncsford; Francis L Martin
Journal:  Environ Health Perspect       Date:  2007-12       Impact factor: 9.031

10.  A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients.

Authors:  Claire J Searle; Ian W Brock; Simon S Cross; Sabapathy P Balasubramanian; Malcolm Wr Reed; Angela Cox
Journal:  Springerplus       Date:  2012-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.